Publications by authors named "Leo Faion"

Claim this Profile
P
Physicochemical and Computational Study of the Encapsulation of Resv-4'-LA and Resv-4'-DHA Lipophenols by Natural and HP-β-CDs.
Ana Belén Hernández-Heredia, Dennis Alexander Silva-Cullishpuma, José Pedro Cerón-Carrasco, Ángel Gil-Izquierdo, Jordan Lehoux, Léo Faion

Int J Mol Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in Fragment-based strategies against tuberculosis.
Baptiste Villemagne, Léo Faion, Salia Tangara, Nicolas Willand

Eur J Med Chem· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid and Efficient Access to Novel Bio-Inspired 3-Dimensional Tricyclic SpiroLactams as Privileged Structures via Meyers' Lactamization.
Salia Tangara, Léo Faïon, Catherine Piveteau, Frédéric Capet, Romain Godelier

Pharmaceuticals (Basel)· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the Antitubercular Activity of Anthranilic Acid Derivatives: From MabA (FabG1) Inhibition to Intrabacterial Acidification.
Léo Faïon, Kamel Djaout, Catalin Pintiala, Catherine Piveteau, Florence Leroux

Pharmaceuticals (Basel)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tricyclic SpiroLactams Kill Mycobacteria In Vitro and In Vivo by Inhibiting Type II NADH Dehydrogenases.
Sushovan Dam, Salia Tangara, Claire Hamela, Theo Hattabi, Léo Faïon

J Med Chem· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On the Hunt for Next-Generation Antimicrobial Agents: An Online Symposium Organized Jointly by the French Society for Medicinal Chemistry (Société de Chimie Thérapeutique) and the French Microbiology Society (Société Française de Microbiologie) on 9-10 December 2021.
Kevin Antraygues, Nina Compagne, Francesca Ruggieri, Kamel Djaout, Zainab Edoo

Pharmaceuticals (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening.
Léo Faïon, Kamel Djaout, Rosangela Frita, Catalin Pintiala, Francois-Xavier Cantrelle

Eur J Med Chem· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis